Top 10 similar words or synonyms for cannabidivarin

cannabichromevarin    0.935312

cbdva    0.896400

cannabigerol    0.894609

cbcv    0.875117

cannabidiorcol    0.848156

cbdv    0.836258

cannabigerovarin    0.830902

cannabichromene    0.825622

cbgv    0.824123

cbcva    0.806126

Top 30 analogous words or synonyms for cannabidivarin

Article Example
Cannabidivarin Similarly to CBD, it has 7 double bond isomers and 30 stereoisomers (see: Cannabidiol#Double bond isomers and their stereoisomers). It is not scheduled by Convention on Psychotropic Substances. It is being actively developed by GW Pharmaceuticals (as GWP42006) because of a demonstrated neurochemical pathway for previously-observed anti-epileptic and anti-convulsive action. GW has begun a phase 2 trial for adult epilepsy, and is to begin trials of this CBDV product in children in 2016 in Australia.
Cannabidivarin Cannabidivarin (CBDV) is a non-psychoactive cannabinoid found in "Cannabis". It is a homolog of cannabidiol (CBD), with the side-chain shortened by two methylene bridges (CH units). Plants with relatively high levels of CBDV have been reported in feral populations of "C. indica" ( = "C. sativa" ssp. "indica" var. "kafiristanica") from northwest India, and in hashish from Nepal. CBDV has anticonvulsant effects.
Cannabichromene In a 2015 study, CBC, together with other common phytocannabinoids, appeared to be promising in skin inflammatory conditions. Specifically CBC, cannabidivarin and tetrahydrocannabivarin showed promise to become highly efficient, novel anti-acne agents.
Cannabinoid Although cannabidivarin (CBDV) is usually a minor constituent of the cannabinoid profile, enhanced levels of CBDV have been reported in feral cannabis plants from the northwest Himalayas, and in hashish from Nepal.
Medical cannabis Epidiolex, a cannabis-based product developed by GW Pharmaceuticals for experimental treatment of epilepsy, underwent stage-two trials in the US in 2014. Pairs of phase 3 trials for Dravet syndrome and Lennox-Gastaut syndrome have begun and should be completed in 2015. They are also running a phase 2 study of non-psychoactive cannabidivarin.